Skip to content
Clinical Trials – home
Not recruiting

Comparison of dapagliflozin versus metformin treatment in patients with early stage type 2 diabetes to evaluate survival and complications

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on patients with Type 2 Diabetes who have been diagnosed within the last 4 years. The research compares two different medications: dapagliflozin (which belongs to a group of medicines called SGLT2 inhibitors) and metformin. The purpose is to determine whether treatment with dapagliflozin compared to metformin is more beneficial for patients in the early stages of Type 2 Diabetes.

The study examines how these medications affect patients' survival and prevents complications related to diabetes. These complications include problems with the heart and blood vessels, as well as issues affecting small blood vessels that can lead to problems with the eyes, kidneys, and feet. Participants will receive either dapagliflozin or metformin as oral tablets daily for up to 72 months.

Throughout the study, researchers will monitor various health indicators including blood sugar levels, cholesterol, blood pressure, body weight, and kidney function. They will also track any diabetes-related complications and collect information about the participants' overall health and well-being. The information will be gathered through regular check-ups and through the Swedish National Diabetes Register.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial Treatment Assignment

    You will be randomly assigned to receive either dapagliflozin or metformin treatment

    Both medications are taken orally (by mouth)

    Your doctor will provide specific dosing instructions for your assigned medication

  2. Step 2

    Regular Health Monitoring

    Your health will be monitored through regular measurements of:

    Blood sugar levels (HbA1c)

    Body weight and body mass index (BMI)

    Blood pressure

    Blood cholesterol levels

    Kidney function through urine tests

  3. Step 3

    Follow-up Period

    The study continues until October 2025

    Your health information will be collected through the Swedish National Diabetes Register

    You will complete quality of life questionnaires during the first two years

  4. Step 4

    Health Event Monitoring

    The following health events will be tracked if they occur:

    Heart-related events (such as heart problems or stroke)

    Eye, kidney, or foot complications related to diabetes

    Any hospital stays

    Any need for additional diabetes medications

  5. Step 5

    Treatment Adjustments

    Your medication may be adjusted if needed

    If required, additional diabetes medications might be added to your treatment

    Any changes to your treatment will be recorded and monitored

Who can join the trial?

7 criteria

  • Must have been diagnosed with Type 2 Diabetes within the last 4 years (diagnosis must meet World Health Organization criteria)
  • Must be at least 18 years old (men and women can participate)
  • Must have a Body Mass Index (BMI) between 18.5 and 45 kg/m2 (BMI is a measure of body fat based on height and weight)
  • Must belong to one of these medication groups:
    • Group A: Either never taken diabetes medication, or only taken it briefly (maximum 4 weeks total)
    • Group B: Currently taking or previously took a single oral diabetes medication for more than 4 weeks
    • Must be registered in the Swedish National Diabetes Register and agree to allow access to personal data collection from this register
    • Must be able to understand and sign an informed consent form (a document that explains the study details and patient rights)

Who cannot join the trial?

16 criteria

  • Age below 18 years or above 65 years
  • Previous treatment with SGLT2 inhibitors (medications that help lower blood sugar by causing the kidneys to remove sugar through urine)
  • Previous treatment with metformin (a common diabetes medication that helps control blood sugar levels)
  • History of diabetic ketoacidosis (a serious complication where the body produces high levels of blood acids)
  • Pregnancy or planning to become pregnant
  • Breastfeeding mothers
  • Severe kidney disease or dysfunction
  • Severe liver disease or dysfunction
  • History of pancreatic disease
  • Active cancer or cancer treatment
  • Uncontrolled high blood pressure
  • History of heart attack or stroke in the past 6 months
  • Participation in another clinical trial within the past 30 days
  • Alcohol or substance abuse
  • Mental conditions that could interfere with study compliance
  • Unable to provide informed consent
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Dapagliflozin

    is a medication that belongs to a class called SGLT2 inhibitors. It works by helping the kidneys remove excess sugar from the blood through urine. This medication is used to treat type 2 diabetes and can help reduce the risk of heart and kidney complications in diabetic patients.

  • Metformin

    is a widely used first-line medication for treating type 2 diabetes. It works by reducing the amount of sugar produced by the liver and helping the body respond better to insulin. This medication helps control blood sugar levels and is often prescribed as an initial treatment for newly diagnosed diabetes patients.

What is already known about the treatment

  • Dapagliflozin

    An oral medication belonging to the SGLT2 inhibitor class used in the treatment of Type 2 Diabetes. This drug works by preventing glucose reabsorption in the kidneys, leading to increased glucose excretion in urine and reduced blood sugar levels. It's available in tablet form and is typically taken once daily, offering an alternative treatment approach to traditional diabetes medications with the added benefit of potential cardiovascular protection.

  • Metformin

    A first-line oral medication for Type 2 Diabetes that belongs to the biguanide class of drugs. It works by reducing glucose production in the liver, decreasing glucose absorption in the intestines, and improving insulin sensitivity in body tissues. Typically taken in tablet form once or twice daily with meals, metformin has been widely used for decades and is considered the gold standard in diabetes treatment due to its proven safety profile and effectiveness in blood sugar control.

Investigated diseases

  • Type 2 Diabetes

    A chronic metabolic disorder characterized by high blood sugar levels due to the body's ineffective use of insulin or insufficient insulin production. The condition typically develops gradually, with the pancreas initially producing extra insulin to compensate for insulin resistance. Over time, the body becomes less able to process glucose effectively, leading to elevated blood sugar levels. The condition can affect multiple body systems and is often associated with lifestyle factors such as diet and physical activity. Type 2 diabetes typically appears in adults, though it can develop at any age.

  • Diabetic Retinopathy

    A complication affecting the eyes where diabetes damages the blood vessels in the retina. The condition develops gradually as high blood sugar levels cause changes in the retinal blood vessels, which may swell, leak, or close off completely. The affected blood vessels can cause vision changes and may stimulate the growth of new, abnormal blood vessels on the retina's surface.

  • Diabetic Nephropathy

    A kidney condition that develops gradually in some people with diabetes. The disorder affects the kidneys' filtering system, particularly the tiny blood vessels that filter waste from the blood. High blood sugar levels can damage these blood vessels over time, leading to changes in kidney function. The condition develops slowly over several years.

  • Diabetic Foot

    A condition where diabetes affects the feet through nerve damage and poor circulation. The disorder can cause changes in skin condition, reduced sensation in the feet, and alterations in foot structure. These changes develop gradually and can affect how the feet function during daily activities. The condition involves both nerve and blood vessel changes in the feet.

Trial detailsLast updated 4 Nov 2026
Age18+ yearsPhasePhase IIITrial ID2024-516228-33-00Protocol codeSMART-2019Estimated enrolment2 200 patientsSponsorUppsala University

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.